DDInter1607 DDInter1676
Ritonavir is an HIV protease inhibitor that interferes with the reproductive cycle of HIV. Although it was initially developed as an independent antiviral agent, it has been shown to possess advantageous properties in combination regimens with low-dose ritonavir and other protease inhibitors. It is now more commonly used as a booster of other protease inhibitors and is available in both liquid formulations and as capsules. While ritonavir is not an active antiviral agent against hepatitis C virus (HCV) infection, it is added in combination therapies indicated for the treatment of HCV infections as a booster. Ritonavir is a potent CYP3A inhibitor that increases peak and trough plasma drug concentrations of other protease inhibitors such as and overall drug exposure. American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) guidelines recommend ritonavir-boosted combination therapies as first-line therapy for HCV Genotype 1a/b and
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Ritonavir {u} (Compound) resembles {v} (Compound) Atazanavir
Ritonavir {u} (Compound) resembles {v} (Compound) Lopinavir
Ritonavir {u} (Compound) treats {v} (Disease) acquired immunodeficiency syndrome
Ritonavir {u} (Compound) binds {v} (Gene) SLCO1A2
Ritonavir {u} (Compound) upregulates {v} (Gene) AGR2
Ritonavir {u} (Compound) is included by {v} (Pharmacologic Class) Breast Cancer Resistance Protein Inhibitors
Ritonavir {u} (Compound) downregulates {v} (Gene) NT5DC2
Ritonavir {u} (Compound) causes {v} (Side Effect) Blood triglycerides increased
Ritonavir (Compound) resembles Atazanavir (Compound)
Ritonavir (Compound) resembles Lopinavir (Compound)
Ritonavir (Compound) treats acquired immunodeficiency syndrome (Disease)
Ritonavir (Compound) binds SLCO1A2 (Gene)
Ritonavir (Compound) upregulates AGR2 (Gene)
Ritonavir (Compound) is included by Breast Cancer Resistance Protein Inhibitors (Pharmacologic Class)
Ritonavir (Compound) downregulates NT5DC2 (Gene)
Ritonavir (Compound) causes Blood triglycerides increased (Side Effect)